ITI Pharma & Healthcare Fund - Growth - Regular Plan

Other Plans and Options
  • (-0.02%)Nav, as on 12-09-2025

  • Previous Nav

  • Net Change on 12-09-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 -1.63 22.87 19.06 1.80 8,357.03
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option Jul 13, 2018 3.41 28.37 21.82 1.88 6,161.81
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 3.61 26.15 20.80 1.93 3,963.38
Mirae Asset Healthcare Fund -Regular Growth Jul 02, 2018 -0.01 21.86 19.12 1.93 2,795.84
Tata India Pharma & Healthcare Fund-Regular Plan-Growth Dec 28, 2015 -1.47 23.49 19.42 2.10 1,308.56

Fund Holdings as on 31-August-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Apollo Hospitals Enterprise Limited

  • Max Healthcare Institute Limited

  • Torrent Pharmaceuticals Limited

  • Cohance Lifesciences Limited

  • Fortis Healthcare Limited

  • Aurobindo Pharma Limited

  • Aster DM Healthcare Limited

  • Lupin Limited

  • Mankind Pharma Limited

  • Alkem Laboratories Limited

  • Wockhardt Limited

  • Neuland Laboratories Limited

  • Abbott India Limited

  • Cipla Limited

  • Net Receivables / (Payables)

  • Dr. Reddy's Laboratories Limited

  • Healthcare Global Enterprises Limited

  • Sai Life Sciences Limited

  • Sumitomo Chemical India Limited

  • Vijaya Diagnostic Centre Limited

  • FDC Limited

  • Rainbow Childrens Medicare Limited

  • Laurus Labs Limited

  • IPCA Laboratories Limited

  • SBI Life Insurance Company Limited

  • Orchid Pharma Limited

  • Standard Glass Lining Technology Ltd

  • Onesource Specialty Pharma Limited

  • Sagility India Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Supriya Lifescience Limited

  • SRF Limited

  • Shilpa Medicare Limited

  • Caplin Point Laboratories Limited

  • Linde India Limited

  • Navin Fluorine International Limited

  • Glenmark Pharmaceuticals Limited

  • UPL Limited

  • Biocon Limited

  • Zydus Lifesciences Limited

  • Syngene International Limited

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Pesticides & Agrochemicals

  • Miscellaneous

  • Chemicals

  • Business Support

  • Insurance

  • Engineering - Industrial Equipments

  • Industrial Gases & Fuels

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹226.89 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended down ₹0(-0.02%)yesterday to ₹16.448.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com